CDK4/6i beyond progression will have a role in metastatic #BreastCancer, but a correct #Biomarker implementation will be crucial. Intriguing #LiquidBiopsy data suggest a potential added benefit in ESR1 mutated #MBC. Similar to PADA-1, unlike MAINTAIN #ctDNA #PrecisionMedicine